Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice

Journal of Neurochemistry

Volumn 97, Issue 4, 2006, Pages 979-991

  Vacher, Claire Marie ^a   Gassmann, Martin ^a   Desrayaud, Sandrine ^b   Challet, Etienne ^c   Bradaia, Amyaouch ^a   Hoyer, Daniel ^b   Waldmeier, Peter ^b   Kaupmann, Klemens ^b   Pévet, Paul ^c   Bettler, Bernhard ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Institut des Neurosciences Cellulaires et Intégratives UPR3212   (France)

Author keywords

Dopamine; GABAB receptors; Hyperlocomotor activity; Tyrosine hydroxylase

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MESSENGER RNA; SERINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN ELECTROPHYSIOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HYPERACTIVITY; HYPERDOPAMINERGIA; KNOCKOUT MOUSE; LOCOMOTION; MICRODIALYSIS; MOUSE; NEGATIVE FEEDBACK; NEUROPHARMACOLOGY; NONHUMAN; NOVELTY; PRIORITY JOURNAL; TELEMETRY;

ANIMALS; BINDING SITES; BRAIN DISEASES, METABOLIC; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; EXTRACELLULAR FLUID; GAMMA-AMINOBUTYRIC ACID; HYPERKINESIS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURAL INHIBITION; NEURAL PATHWAYS; RECEPTORS, DOPAMINE D1; RECEPTORS, GABA-B; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

ANIMALIA;

EID: 33646110243     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.03806.x     Document Type: Article

References (52)

1. Andersson K. K. Vassort C. Brennan B. A. Que L. Jr. Haavik J. Flatmark T. Gros F. Thibault J. 1992 Purification and characterization of the blue-green rat phaeochromocytoma (PC12) tyrosine hydroxylase with a dopamine-Fe(III) complex. Reversal of the endogenous feedback inhibition by phosphorylation of serine-40. Biochem. J. 284 687 695.
2. B receptor antagonist, CGP 56999A. Eur. J. Pharmacol. 333 135 142.
3. Bettler B. Kaupmann K. Mosbacher J. Gassmann M. 2004 Molecular structure and physiological functions of GABA(B) receptors. Physiol. Rev. 84 835 867.
4. B receptors, in Pharmacology Communications Vol. 2 23. Harwood Academic Publishers GmbH Chur, Switzerland.
5. Bostwick J. R. Le W. D. 1991 A tyrosine hydroxylase assay in microwells using coupled non-enzymatic decarboxylation of dopa. Anal Biochem. 192 125 130.
6. B receptors: structure and function. Pharmacol. Rev. 54 247 264.
7. Chen G. van den Pol A. N. 1998 Presynaptic GABAB autoreceptor modulation of P/Q-type calcium channels and GABA release in rat suprachiasmatic nucleus neurons. J. Neurosci. 18 1913 1922.
8. Chester J. A. Cunningham C. L. 1999 Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol. Biochem. Behav. 63 325 331.
9. (B) receptor inhibition causes locomotor stimulation in mice. Eur. J. Pharmacol. 433 101 104.
10. Crosio C. Cermakian N. Allis C. D. Sassone-Corsi P. 2000 Light induces chromatin modification in cells of the mammalian circadian clock. Nat. Neurosci. 3 1241 1247.
11. Cruz H. G. Ivanova T. Lunn M. L. Stoffel M. Slesinger P. A. Luscher C. 2004 Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat. Neurosci. 7 153 159.
12. Cryan J. F. Kaupmann K. 2005 Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol. Sci. 26 36 43.
13. Cryan J. F. Kelly P. H. Chaperon F. Gentsch C. Mombereau C. Lingenhoehl K. Froestl W. Bettler B. Kaupmann K. Spooren W. P. 2004 Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J. Pharmacol. Exp. Ther. 310 952 963.
14. De Vente J. Hopkins D. A. Markerink-Van Ittersum M. Emson P. C. Schmidt H. H. Steinbusch H. W. 1998 Distribution of nitric oxide synthase and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain. Neuroscience 87 207 241.
15. Engberg G. Kling-Petersen T. Nissbrandt H. 1993 GABAB-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse 15 229 238.
16. B receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 365 173 180.
17. Franklin K. B. J. Paxinos G. 1997 The Mouse Brain in Stereotaxic Coordinates. Academic Press San Diego.
18. Gainetdinov R. R. Jones S. R. Caron M. G. 1999 Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry 46 303 311.
19. Gassmann M. Shaban H. Vigot R. et al. 2004 Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. J. Neurosci. 24 6086 6097.
20. Gillespie C. F. Mintz E. M. Marvel C. L. Huhman K. L. Albers H. E. 1997 GABA(A) and GABA(B) agonists and antagonists alter the phase-shifting effects of light when microinjected into the suprachiasmatic region. Brain Res. 759 181 189.
21. Giros B. Jaber M. Jones S. R. Wightman R. M. Caron M. G. 1996 Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 606 612.
22. Jaber M. Dumartin B. Sagne C. Haycock J. W. Roubert C. Giros B. Bloch B. Caron M. G. 1999 Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur. J. Neurosci. 11 3499 3511.
23. Jones S. R. Gainetdinov R. R. Wightman R. M. Caron M. G. 1998a Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18 1979 1986.
24. Jones S. R. Gainetdinov R. R. Jaber M. Giros B. Wightman R. M. Caron M. G. 1998b Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl Acad. Sci. USA 95 4029 4034.
25. Jones S. R. Gainetdinov R. R. Hu X. T. Cooper D. C. Wightman R. M. White F. J. Caron M. G. 1999 Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat. Neurosci. 2 649 655.
26. Kaneda N. Sasaoka T. Kobayashi K. et al. 1991 Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice. Neuron 6 583 594.
27. B(1)-deficient mice. Eur. J. Neurosci. 18 2722 2730.
28. Kumer S. C. Vrana K. E. 1996 Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67 443 462.
29. Le Moal M. ed. ( 1995 Mesocorticolimbic Dopaminergic Neurons pp. 283 294. Raven Press New York.
30. Lindgren N. Xu Z. Q. Herrera-Marschitz M. Haycock J. Hokfelt T. Fisone G. 2001 Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur. J. Neurosci. 13 773 780.
31. Lindgren N. Usiello A. Goiny M. Haycock J. Erbs E. Greengard P. Hokfelt T. Borrelli E. Fisone G. 2003 Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc. Natl Acad. Sci. USA 100 4305 4309.
32. B receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J. Pharmacol. Exp. Ther. 287 261 265.
33. Maharjan S. Serova L. Sabban E. L. 2005 Transcriptional regulation of tyrosine hydroxylase by estrogen: opposite effects with estrogen receptors α and β and interactions with cyclic AMP. J. Neurochem. 93 1502 1514.
34. Mombereau C. Kaupmann K. Froestl W. Sansig G. van der Putten H. Cryan J. F. 2004 Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29 1050 1062.
35. Phillis B. D. Ong J. White J. M. Bonnielle C. 2001 Modification of d-amphetamine-induced responses by baclofen in rats. Psychopharmacology 153 277 284.
36. B(1)-deficient mice. Mol. Cell Neurosci. 17 1059 1070.
37. Quéva C. Bremner-Danielsen M. Edlund A. Ekstrand A. J. Elg S. Erickson S. Johansson T. Lehmann A. Mattsson J. P. 2003 Effects of GABA agonists on body temperature regulation in mice. Br. J Pharmacol. 140 315 322.
38. Ralph M. R. Menaker M. 1989 GABA regulation of circadian responses to light. I. Involvement of GABAA-benzodiazepine and GABAB receptors. J. Neurosci. 9 2858 2865.
39. Ruttimann E. Vacher C. M. Gassmann M. Kaupmann K. Van der Putten H. Bettler B. 2004 Altered hippocampal expression of calbindin-D-28k and calretinin in GABA(B(1))-deficient mice. Biochem. Pharmacol. 68 1613 1620.
40. B(1). Neuron 31 47 58.
41. Slattery D. A. Desrayaud S. Cryan J. F. 2005a GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. J. Pharmacol. Exp. Ther. 312 290 296.
42. Slattery D. A. Markou A. Froestl W. Cryan J. F. 2005b The GABA(B) receptor-positive modulator GS39783 and the GABA(B) receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology 20 2065 2072.
43. Smolders I. De Klippel N. Sarre S. Ebinger G. Michotte Y. 1995 Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. Eur. J. Pharmacol. 284 83 91.
44. Spielewoy C. Roubert C. Hamon M. Nosten-Bertrand M. Betancur C. Giros B. 2000 Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol. 11 279 290.
45. Spooren W. P. Vassout A. Waldmeier P. Gentsch C. 1998 Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity. Eur. J. Pharmacol. 353 1 4.
46. Stork O. Hashimoto T. Obata K. 1994 Haloperidol activates tyrosine hydroxylase gene-expression in the rat substantia nigra, pars reticulata. Brain Res. 633 213 222.
47. B receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol. Pharmacol. 60 963 971.
48. Urwyler S. Pozza M. F. Lingenhoehl K. Mosbacher J. Lampert C. Froestl W. Koller M. Kaupmann K. 2003 N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of γ-aminobutyric acid B receptor function. J. Pharmacol. Exp. Ther. 307 322 330.
49. Vacher C. M. Fretier P. Creminon C. Calas A. Hardin-Pouzet H. 2002 Activation by serotonin and noradrenaline of vasopressin and oxytocin expression in the mouse paraventricular and supraoptic nuclei. J. Neurosci. 22 1513 1522.
50. A receptors to a dopamine hyperfunction. Proc. Natl Acad. Sci. USA 102 17 154 17 159.
51. Yoshida M. Yokoo H. Tanaka T. Emoto H. Tanaka M. 1994 Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. Brain Res. 636 111 114.
52. Zoltay G. Cooper J. R. 1994 Presynaptic modulation by dopamine and GABA opens a potassium channel in rat cortical, striatal and hippocampal synaptosomes via eicosanoids. Neurochem. Int. 25 345 348.